Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H6N2 |
| Molecular Weight | 82.1038 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NNC=C1
InChI
InChIKey=XKVUYEYANWFIJX-UHFFFAOYSA-N
InChI=1S/C4H6N2/c1-4-2-3-5-6-4/h2-3H,1H3,(H,5,6)
| Molecular Formula | C4H6N2 |
| Molecular Weight | 82.1038 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. | 2010-12-01 |
|
| An effective procedure for the synthesis of acid-sensitive epoxides: use of 1-methylimidazole as the additive on methyltrioxorhenium-catalyzed epoxidation of alkenes with hydrogen peroxide. | 2010-05-21 |
|
| Gateways to clinical trials. | 2010-05 |
|
| NMR and theoretical study on interactions between diperoxovanadate complex and pyrazole-like ligands. | 2010-03 |
|
| A novel tripodal ligand containing three different N-heterocyclic donor functions and its application in catechol dioxygenase mimicking. | 2009 |
|
| Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. | 2008-04 |
|
| Pyrazole and methylpyrazole for the treatment of 2-butoxyethanol poisoning. | 2007-08-02 |
|
| An improved methyltrioxorhenium-catalyzed epoxidation of alkenes with hydrogen peroxide. | 2007-07-07 |
|
| Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. | 2007-06-15 |
|
| Characterization of peptide-pyrazole interactions in solution by low-temperature NMR studies. | 2007 |
|
| Methylpyrazole-capped two-dimensional supramolecular M(II) (M = Mn, Ni, Co) assemblies constructed by covalent and noncovalent interactions: uncommon coordination modes of methylpyrazoles and magnetic properties. | 2006-07-24 |
|
| Formation of 4'-carboxyl acid metabolite of imrecoxib by rat liver microsomes. | 2006-04 |
|
| Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib. | 2006-03 |
|
| From model compounds to protein binding: syntheses, characterizations and fluorescence studies of [RuII(bipy)(terpy)L]2+ complexes (bipy = 2,2'-bipyridine; terpy = 2,2':6',2''-terpyridine; L = imidazole, pyrazole and derivatives, cytochrome c). | 2005-01-21 |
|
| Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes. | 2004-02 |
|
| Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of acute ethylene glycol poisoning. | 2002-09 |
|
| Spectroscopic study on charge transfer molecular complexes of pyrazole derivatives with some pi-electron acceptors. | 2002-07 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:49:38 GMT 2025
by
admin
on
Mon Mar 31 19:49:38 GMT 2025
|
| Record UNII |
W7KU1RRO6U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
215-925-7
Created by
admin on Mon Mar 31 19:49:38 GMT 2025 , Edited by admin on Mon Mar 31 19:49:38 GMT 2025
|
PRIMARY | |||
|
300000053090
Created by
admin on Mon Mar 31 19:49:38 GMT 2025 , Edited by admin on Mon Mar 31 19:49:38 GMT 2025
|
PRIMARY | |||
|
W7KU1RRO6U
Created by
admin on Mon Mar 31 19:49:38 GMT 2025 , Edited by admin on Mon Mar 31 19:49:38 GMT 2025
|
PRIMARY | |||
|
1453-58-3
Created by
admin on Mon Mar 31 19:49:38 GMT 2025 , Edited by admin on Mon Mar 31 19:49:38 GMT 2025
|
PRIMARY | |||
|
15073
Created by
admin on Mon Mar 31 19:49:38 GMT 2025 , Edited by admin on Mon Mar 31 19:49:38 GMT 2025
|
PRIMARY | |||
|
DTXSID3073260
Created by
admin on Mon Mar 31 19:49:38 GMT 2025 , Edited by admin on Mon Mar 31 19:49:38 GMT 2025
|
PRIMARY |